{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:44:20Z","timestamp":1785527060799,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01262-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:33:11Z","timestamp":1780389191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Context-of-use\u2013Guided Development and Validation of a Transthyretin Immunoassay: A Framework for Biomarker Assay Design"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2193-9168","authenticated-orcid":false,"given":"Tanya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6859-7800","authenticated-orcid":false,"given":"John","family":"Canfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0714-4774","authenticated-orcid":false,"given":"Erin","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8302-8118","authenticated-orcid":false,"given":"Leighla","family":"Tayefeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-8026","authenticated-orcid":false,"given":"John L.","family":"Allinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5080-3037","authenticated-orcid":false,"given":"Nicholas J.","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-8080","authenticated-orcid":false,"given":"Joel A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"3","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C. A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408\u201327.","journal-title":"Brain"},{"issue":"1","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS \u2013 the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","volume":"4","author":"E Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez E, et al. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol. 2022;4(4):442\u201354.","journal-title":"JACC CardioOncol"},{"issue":"10","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1262_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83(2):152\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1262_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"L-L Mariani","year":"2015","unstructured":"Mariani L-L, et al. Genotype\u2013phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78(6):901\u201316.","journal-title":"Ann Neurol"},{"issue":"9","key":"1262_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2011","unstructured":"Sattianayagam PT, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2011;33(9):1120\u20137.","journal-title":"Eur Heart J"},{"issue":"12","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1515\/CCLM.2002.208","volume":"40","author":"J Robbins","year":"2002","unstructured":"Robbins J. Transthyretin from discovery to now. Clin Chem Lab Med. 2002;40(12):1183\u201390.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbapap.2004.09.023","volume":"1703","author":"P Raghu","year":"2004","unstructured":"Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta. 2004;1703(1):1\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1262_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.sbi.2009.12.009","volume":"20","author":"S Connelly","year":"2010","unstructured":"Connelly S, et al. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol. 2010;20(1):54\u201362.","journal-title":"Curr Opin Struct Biol"},{"issue":"12","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/ar020073i","volume":"38","author":"SM Johnson","year":"2005","unstructured":"Johnson SM, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38(12):911\u201321.","journal-title":"Acc Chem Res"},{"issue":"15","key":"1262_CR12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, et al. Eplontersen for hereditary Transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358.","journal-title":"JAMA"},{"issue":"2","key":"1262_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11(2):e004000.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"1262_CR14","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1021\/acs.jproteome.6b00998","volume":"16","author":"GG Chan","year":"2017","unstructured":"Chan GG, Koch CM, Connors LH. Blood proteomic profiling in inherited (ATTRm) and acquired (ATTRwt) forms of transthyretin-associated cardiac amyloidosis. J Proteome Res. 2017;16(4):1659\u201368.","journal-title":"J Proteome Res"},{"issue":"6","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1208\/s12248-017-0146-9","volume":"19","author":"KJ Cowan","year":"2017","unstructured":"Cowan KJ, et al. Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material. AAPS j. 2017;19(6):1550\u201363.","journal-title":"AAPS j"},{"issue":"1","key":"1262_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jim.2013.08.009","volume":"397","author":"BA Leary","year":"2013","unstructured":"Leary BA, et al. Bioanalytical platform comparison using a generic human IgG PK assay format. J Immunol Methods. 2013;397(1):28\u201336.","journal-title":"J Immunol Methods"},{"issue":"2","key":"1262_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11095-005-9045-3","volume":"23","author":"JW Lee","year":"2006","unstructured":"Lee JW, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312\u201328.","journal-title":"Pharm Res"},{"issue":"2","key":"1262_CR18","doi-asserted-by":"publisher","first-page":"E260","DOI":"10.1208\/aapsj0902029","volume":"9","author":"JW Findlay","year":"2007","unstructured":"Findlay JW, Dillard RF. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007;9(2):E260\u20137.","journal-title":"AAPS J"},{"issue":"3","key":"1262_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12248-018-0208-7","volume":"20","author":"Y Xiang","year":"2018","unstructured":"Xiang Y, et al. A simple approach to determine a curve fitting model with a correct weighting function for calibration curves in quantitative ligand binding assays. AAPS J. 2018;20(3):45.","journal-title":"AAPS J"},{"key":"1262_CR20","unstructured":"Piccoli SP, Brad Ackermann JMS, Allinson J, Arnold M, Amur S. Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices. C \u2013 Path; 2019."},{"issue":"suppl_4","key":"1262_CR21","doi-asserted-by":"publisher","first-page":"16427","DOI":"10.1073\/pnas.202495199","volume":"99","author":"P Hammarstr\u00f6m","year":"2002","unstructured":"Hammarstr\u00f6m P, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci. 2002;99(suppl_4):16427\u201332.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1262_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, et al. Inotersen treatment for patients with hereditary Transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"38","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"11442","DOI":"10.1021\/bi011194d","volume":"40","author":"X Jiang","year":"2001","unstructured":"Jiang X, et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry. 2001;40(38):11442\u201352.","journal-title":"Biochemistry"},{"issue":"6","key":"1262_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1208\/s12248-025-01135-5","volume":"27","author":"YG Ni","year":"2025","unstructured":"Ni YG, et al. Why is biomarker assay validation different from that of pharmacokinetic assays? AAPS J. 2025;27(6):147.","journal-title":"AAPS J"},{"issue":"7","key":"1262_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","volume":"62","author":"LN van der Vorm","year":"2016","unstructured":"van der Vorm LN, et al. Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. Clin Chem. 2016;62(7):993\u20131001.","journal-title":"Clin Chem"},{"issue":"1","key":"1262_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jnc.14569","volume":"149","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer B, et al. Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem. 2019;149(1):126\u201338.","journal-title":"J Neurochem"},{"issue":"6","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1373\/clinchem.2005.048629","volume":"51","author":"NS Schoonenboom","year":"2005","unstructured":"Schoonenboom NS, et al. Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. Clin Chem. 2005;51(6):1057\u201360.","journal-title":"Clin Chem"},{"key":"1262_CR28","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2025-0667","author":"B Arslan","year":"2025","unstructured":"Arslan B, et al. Method comparison of plasma and CSF GFAP immunoassays across multiple platforms. Clinical Chemistry and Laboratory Medicine (CCLM). 2025. https:\/\/doi.org\/10.1515\/cclm-2025-0667.","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"23","key":"1262_CR29","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.4155\/bio-2018-0279","volume":"10","author":"S Keller","year":"2018","unstructured":"Keller S, Purushothama S. Biomarker assays: is it time for a standalone regulatory guidance? Bioanalysis. 2018;10(23):1893\u20135.","journal-title":"Bioanalysis"},{"issue":"20","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.4155\/bio-2020-0243","volume":"12","author":"J Goodman","year":"2020","unstructured":"Goodman J, et al. Update to the European Bioanalysis Forum recommendation on biomarkers assays; bringing context of use into practice. Bioanalysis. 2020;12(20):1427\u201337.","journal-title":"Bioanalysis"},{"key":"1262_CR31","unstructured":"Health NIO. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Bethesda (MD). 2016."},{"issue":"10","key":"1262_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102405","volume":"10","author":"K Krueger","year":"2022","unstructured":"Krueger K, et al. High quality performance of novel immunoassays for the sensitive quantification of soluble PD-1, PD-L1 and PD-L2 in blood. Biomedicines. 2022;10(10):2405.","journal-title":"Biomedicines"},{"issue":"1","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jim.2011.06.020","volume":"371","author":"CI Soderstrom","year":"2011","unstructured":"Soderstrom CI, et al. Comparison of four distinct detection platforms using multiple ligand binding assay formats. J Immunol Methods. 2011;371(1):106\u201313.","journal-title":"J Immunol Methods"},{"key":"1262_CR34","doi-asserted-by":"publisher","first-page":"935382","DOI":"10.3389\/fneur.2022.935382","volume":"13","author":"S Lee","year":"2022","unstructured":"Lee S, et al. Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform. Front Neurol. 2022;13:935382.","journal-title":"Front Neurol"},{"issue":"1","key":"1262_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41120-021-00050-1","volume":"8","author":"J Mathews","year":"2022","unstructured":"Mathews J, et al. Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report. AAPS Open. 2022;8(1):2.","journal-title":"AAPS Open"},{"issue":"8","key":"1262_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/bio-2017-0009","volume":"9","author":"N Dakappagari","year":"2017","unstructured":"Dakappagari N, et al. Recommendations for clinical biomarker specimen preservation and stability assessments. Bioanalysis. 2017;9(8):643\u201353.","journal-title":"Bioanalysis"},{"issue":"14","key":"1262_CR37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501772R","volume":"39","author":"AS Yadav","year":"2025","unstructured":"Yadav AS, et al. Sex and age but not body mass index (BMI) predict serum retinol binding protein 4 (RBP4) and transthyretin (TTR) concentrations. FASEB J. 2025;39(14):e70842.","journal-title":"FASEB J"},{"issue":"4","key":"1262_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506120802525285","volume":"15","author":"J Buxbaum","year":"2008","unstructured":"Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid. 2008;15(4):255\u201361.","journal-title":"Amyloid"},{"key":"1262_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli L, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023;14:1242815.","journal-title":"Front Neurol"},{"issue":"9","key":"1262_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/ph17091225","volume":"17","author":"A Chakrabartty","year":"2024","unstructured":"Chakrabartty A. Structural basis for monoclonal antibody therapy for transthyretin amyloidosis. Pharmaceuticals. 2024;17(9):1225.","journal-title":"Pharmaceuticals"},{"key":"1262_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson U, et al. A practical guide to immunoassay method validation. Front Neurol. 2015;6:179.","journal-title":"Front Neurol"},{"key":"1262_CR42","volume":"2012","author":"TA Ellis","year":"2012","unstructured":"Ellis TA, et al. The relationship between different assays for detection and quantification of Amyloid Beta 42 in human cerebrospinal fluid. Int J Alzheimers Dis. 2012;2012:984746.","journal-title":"Int J Alzheimers Dis"},{"issue":"2","key":"1262_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","volume":"1","author":"R Mayeux","year":"2004","unstructured":"Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182\u20138.","journal-title":"NeuroRx"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01262-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:23Z","timestamp":1785521303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01262-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01262-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TW, NV, and JM are employees of Ionis, developers of Eplontersen described in this article. JC and JLA are employees of Immunologix Labs.","order":1,"name":"Ethics","label":"Financial Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI was used to review and help write the article. No AI was used for figure or table generation.","order":2,"name":"Ethics","label":"A.I. Disclosure Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}